At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 28 enrolled
Drug / intervention
Pitavastatin (NK-104) +1 moredrug
Likely dose
Diltiazem (Cardizem LA) 240 mg QDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug-Drug Interaction Study to Assess the Effects of Steady-State Cardizem LA (Diltiazem Hydrochloride) and Steady-State Pitavastatin on Their Respective Pharmacokinetics in Healthy Adult Volunteers
In Brief
A Phase 4 clinical trial evaluating Pitavastatin (NK-104) and Diltiazem (Cardizem LA) 240 mg QD for Healthy. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This is a Phase 4, single-center, open-label, fixed-sequence, multiple-dose, 2-way drug-drug interaction study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
Primary CompletionJun 2011
Study CompletionJul 2011
First PostedAug 2011
TodayJul 2026
First PostedAug 24, 2011
Enrollment StartMay 1, 2011
Primary CompletionJun 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.9 years ago
Interventions
Pitavastatin (NK-104)drug
pitavastatin (NK-104) 4 mg once daily (QD)
Diltiazem (Cardizem LA) 240 mg QDdrug
Diltiazem (Cardizem LA) 240 mg QD